CYP2C19基因检测指导我国急性冠脉综合征患者抗血小板治疗方案的药物经济学评价  

Pharmacoeconomics Evaluation of CYP2C19 Genetic Test Guiding Antiplatelet Therapy for Acute Coronary Syndrome Patients in China

作　　者：曹爱霖[1] 钱皎[1] 王卓[1] 

机构地区：[1]上海长海医院药学部,上海200433

出　　处：《中国药房》2017年第23期3183-3187,共5页China Pharmacy

摘　　要：目的:从药物经济学角度评价我国拟行介入手术的急性冠脉综合征(ACS)患者依据CYP2C19基因指导抗血小板药物应用的可行性。方法:基于全球范围内的PLATO试验数据,依据治疗策略将患者分为3组(氯吡格雷组、替格瑞洛组、基因检测组)。通过运用TreeagePro 2011软件构建短期决策树模型及长期Markov模型,导入我国相关数据,评价不同治疗策略的成本-效果。结果与结论:针对ACS患者,根据我国国内生产总值水平,常规应用替格瑞洛对自费患者及上海市的医保患者更具药物经济学优势,而CYP2C19基因检测指导抗血小板药物应用在全国范围的医保患者中更具有药物经济学优势。OBJECTIVE：To evaluate the feasibility of using CYP2C19 gene to guide the use of antiplatelet agents in acute coronary syndrome（ACS） patients undergoing interventional operation in China from the viewpoint of pharmacoeconomics. METHODS：Based on global PLATO trial data,the patients were divided into 3 groups according to treatment strategies（clopidogrel group,ticagrelor group,genetic test group）. By applying Treeage Pro 2011 software,short-term decision tree model and long-term Markov model were established,and related data were imported to evaluate cost-effectiveness of different treatment strategies. RESULTSCONCLUSIONS：For ACS patients,according to the level of GDP in China,conventional use of ticagrelor is of pharmacoeconomic advantage for in Shanghai and uninsured patients insured patients;the use of antiplatelet agents guided by CYP2C19 gene test is of pharmacoeconomic advantage among nationwide insured patients.

关 键 词：替格瑞洛 氯吡格雷 基因检测 药物经济学 成本-效果分析 CYP2C19基因 

分 类 号：R956[医药卫生—药学] R349.55